Neuroleptic malignant syndrome and neuropsychiatric sequelaes: A retrospective study;Nöroleptik malign sendrom ve nöropsikiyatrik sekelleri: Geriye dönük bir araştirma

Klinik Psikofarmakoloji Bulteni

Volumn 16, Issue 1, 2006, Pages 31-34

  Yumru, Mehmet ^a   Savaş, Haluk A ^a   Cansel, Neslihan ^a   Özen, Murat Eren ^b   Kandemir, Hasan ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Psikiyatri ^*  (Turkey)

Author keywords

Complication; Neuroleptic malignant syndrome; Neuropsychiatric sequelae

Indexed keywords

ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FLEXION CONTRACTURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGICAL COMPLICATION; PARKINSONISM; RIGIDITY; SYMPTOMATOLOGY;

EID: 33645554332     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kaplan HI, Sadock B, Grebb JA. Synopsis of Psychiatry. 8. Baski, Baltimore, Williams& Wilkins 1994:953
2. Yüksel N, Köroǧlu E. Nöroleptik malign sendrom. Klinik Uygulamali psikofarmakoloji. Ankara. Hekimler Yayin Birliǧi 1991:91-97
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4.baski,Washington DC, American Psychiatric Association 1994:739-742
4. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998;155:1113-1116
5. Sing KJ, Ramaekers GM, Van Harten PN. Neuroleptic malignant syndrome and quetiapine. Am J Psychiatry 2002;159:149-150
6. Bora E, Gönül AS, Akdeniz F, Vahip S. Neuroleptic malignant-like syndrome induced with low-dose quetiapine treated with electroconvulsive therapy. European Psychiatry 2003;18:322-323
7. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986;73:337-347
8. Gelder MG, Gath D, Mayou R. The Neuroleptic Malignant Syndrome. Oxford Texbook of Psychiatry, Third edition, Oxford University Pres 1996:554-555
9. Ingall TJ, Tennant C. Neuroleptic malignant syndrome. Med J Aust 1986;145:454-455
10. Adityanjee, Sajatovic M, Munshi KR. Neuropsychiatric Sequelae of Neuroleptic Malignant Syndrome. Clin Neuropharmacol 2005;28:197-204
11. Allstop P, Twigley Aj. The neuroleptic malignant syndrome. Anaesthesia 1987;42:49-53
12. Yumru M, Savas HA, Savas E. Tek Doz Klorpromazin Uygulamasi Sonrasi Gelişen ve Elektrokonvulsif Tedaviye Olumlu Yanit Veren Nöroleptik Malign Sendrom: Olgu Sunumu. Türkiye'de Psikiyatri 2005;7:126-128
13. Özen ME, Yumru M, Herken H, Sava. HA. Ziprasidon Tedavisinin İkinci Gününde Gelişen Nöroleptik Malign Sendrom: Olgu Sunumu. 41.Ulusal Psikiyatri Kongresi Bildiri Kitabi 2005:210
14. Koponen H, Repo E, Lepola U. Long-term outcome after neuroleptic malignant syndrome. Acta Psychiatr Scand 1991;84:550-551
15. Black KJ, Racette B, Perlmutter JS. Preventing contractures in neuroleptic malignant syndrome and dystonia. Am J Psychiatry 1998;155:1298-1299
16. Craddock B, Craddock N. Contractures in neuroleptic malignant syndrome. Am J Psychiatry 1997;154;436
17. Buckley P, Freyne A, McCarthy A, Larkin C. Neuroleptic malignant syndrome follow-up study. Ir J Med Sci 1991;160:45-47
18. Lee S, Merriam A, Kim TS, Liebling M, Dickson DW, Moore GR. Cerebellar degeneration in neuroleptic malignant syndrome: neuropathologic findings and review of the literature concerning heat-related nervous system injury. J Neurol Neurosurg Psychiatry 1989;52:387-391
19. Van Harten PN, Kemperman CJF. Organic amnestic disorder: a long-term sequel after neuroleptic malignant syndrome. Biol Psychiatry 1991;29:407-410